MAGNITE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MAGNITE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $48.49M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $37.64M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $37.87M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $32.42M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $41.43M | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $29.73M | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | $28.65M | Feb 27, 2020 |
| FY2019 | Mar 31, 2018 | $24.88M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $31.40M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $35.21M | Mar 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.95M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $668.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $619.71M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $577.07M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $468.41M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $82.00M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $60.98M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $42.35M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $36.30M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $48.49M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.61M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $22.79M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($159.18M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($130.32M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $65.0K | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $5.89M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($10.52M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($39.13M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($9.68M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $1.52M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.60M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $51.09M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($155.01M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($112.78M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($81.07M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $8.00M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($10.94M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($40.56M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($10.73M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $986.0K | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $95.24M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $94.32M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $93.76M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $74.45M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $14.23M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $13.56M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $13.06M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $10.69M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $10.40M | Feb 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $235.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $214.37M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $192.55M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $126.59M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($12.07M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $31.98M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($22.69M) | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $21.54M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $60.12M | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.54M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $32.81M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $26.76M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $30.82M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $17.70M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $14.29M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $11.43M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $11.43M | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $32.44M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $23.48M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.16B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.85B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.69B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.71B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.71B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $938.96M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $395.12M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $360.01M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $383.64M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $519.78M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.09B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.99B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.92B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.83B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $557.35M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $283.18M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $242.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $219.02M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $220.26M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $922.35M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $768.22M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $701.68M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $791.30M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $880.76M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $381.61M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $111.94M | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $118.01M | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $164.61M | Feb 25, 2021 |
| FY2017 | Dec 31, 2016 | $299.51M | Mar 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $983.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $978.22M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $978.22M | Feb 25, 2026 |
| FY2023 | Dec 31, 2022 | $978.22M | Feb 28, 2024 |
| FY2023 | Dec 31, 2021 | $969.87M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $158.13M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $7.37M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $65.71M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($516.56M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($661.17M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($683.96M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($524.77M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($394.45M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($394.52M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($341.08M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($315.61M) | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | ($253.78M) | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | ($99.00M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $553.36M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $483.22M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $326.22M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $326.25M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $230.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $117.68M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $88.89M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $80.45M | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $76.64M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $149.42M | Mar 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $556.11M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $553.75M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $536.59M | Feb 26, 2025 |
| FY2022 | Dec 31, 2022 | $754.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2021 | $758.20M | Feb 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142.96M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 141.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 138.58M | Feb 26, 2025 |
| FY2022 | Dec 31, 2022 | 134.01M | Feb 22, 2023 |
| FY2022 | Dec 31, 2021 | 132.20M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 114.03M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 53.89M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 51.16M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | 50.24M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | 49.38M | Mar 15, 2018 |